Trial Profile
A phase I, Prospective, Open-label, Single centre, Dose escalation study to evaluate the safety and preliminary efficacy of intramuscular injection of pUDK-HGF in patients with Critical Limb Ischemia
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Aug 2018
Price :
$35
*
At a glance
- Drugs PUDK HGF (Primary)
- Indications Chronic limb-threatening ischemia
- Focus Adverse reactions; Therapeutic Use
- 07 Aug 2018 New trial record
- 06 Aug 2018 Results published in the European Journal of Vascular and Endovascular Surgery